Last updated on February 2020

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Brief description of study

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Clinical Study Identifier: NCT03969888

Find a site near you

Start Over

University of Utah /ID# 212350

Salt Lake City, UT United States
  Connect »